Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Omar Azzam, Revathy Carnagarin, Leslie Marisol Lugo-Gavidia, Janis Nolde, Vance B. Matthews & Markus P. Schlaich. (2021) Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opinion on Pharmacotherapy 22:16, pages 2095-2103.
Read now
Read now
Bryce C Simes & Gordon G MacGregor. (2019) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes, Metabolic Syndrome and Obesity 12, pages 2125-2136.
Read now
Read now
Matthew R Weir. (2019) Renal effects of sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. Postgraduate Medicine 131:6, pages 367-375.
Read now
Read now
Sebastian Filippas-Ntekouan, Theodosios D. Filippatos & Moses S. Elisaf. (2018) SGLT2 inhibitors: are they safe?. Postgraduate Medicine 130:1, pages 72-82.
Read now
Read now
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf & George Liamis. (2017) Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 16:10, pages 1121-1132.
Read now
Read now
Vasilios Tsimihodimos, Theodosios D. Filippatos & Moses S. Elisaf. (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 399-408.
Read now
Read now
Christian W. Mende. (2017) Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Current Medical Research and Opinion 33:3, pages 541-551.
Read now
Read now
Thomas C. Blevins & Azeez Farooki. (2017) Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine 129:1, pages 159-168.
Read now
Read now
T. D. Filippatos, V. Tsimihodimos & M. S. Elisaf. (2016) Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy 17:12, pages 1581-1583.
Read now
Read now
Maria Alba, John Xie, Albert Fung & Mehul Desai. (2016) The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 32:8, pages 1375-1385.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Read now
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
Read now
Articles from other publishers (71)
Xiaoling Luo, Jing Xu, Shoulian Zhou, Cheng Xue, Zewei Chen & Zhiguo Mao. (2023) Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD. Clinical Journal of the American Society of Nephrology.
Crossref
Crossref
Mitchell H. Rosner, Nam Ha, Biff F. Palmer & Mark A. Perazella. (2023) Acquired Disorders of Hypomagnesemia. Mayo Clinic Proceedings 98:4, pages 581-596.
Crossref
Crossref
Yasunori Miyamoto, Akira Honda, Seiji Yokose, Mariko Nagata & Jiro Miyamoto. (2023) The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. Journal of Clinical Medicine 12:6, pages 2253.
Crossref
Crossref
Kazuki Shiina, Hirofumi Tomiyama, Atsushi Tanaka, Takumi Imai, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Kaoru Dohi, Haruo Kamiya, Keisuke Kida, Toshihisa Anzai, Taishiro Chikamori, Koichi Node, Masayoshi Ajioka, Junya Ako, Rie Amano, Mitsutoshi Asai, Kazuo Eguchi, Kenichi Eshima, Shinya Fujiki, Masashi Fujita, Shungo Hikoso, Shinya Hiramitsu, Satoshi Hoshide, Akihiko Hoshino, Yuki Ikeda, Yumi Ikehara, Takayuki Inomata, Teruo Inoue, Katsuhisa Ishii, Nobukazu Ishizaka, Masaaki Ito, Noriaki Iwahashi, Katsuomi Iwakura, Toshiaki Kadokami, Takahiro Kanbara, Yumiko Kanzaki, Ken Kashimura, Kazuo Kimura, Satoru Kishi, Shuichi Kitada, Masafumi Kitakaze, Akihiro Kiyosue, Kazuhisa Kodama, Takayuki Kojima, Takumi Kondo, Yoshiaki Kubota, Kenya Kusunose, Noritaka Machii, Kazuo Matsunaga, Yasuto Matsuo, Yashushi Matsuzawa, Takeshi Mikami, Toru Minamino, Toyoaki Murohara, Takahiro Nagai, Yasuko Nagano, Masashi Nagumo, Ikuko Nakamura, Katsunori Nakamura, Daisaku Nakatani, Mamoru Nanasato, Hiriyuki Naruse, Masami Nishino, Shinichi Niwano, Mitsutoshi Oguri, Nobuyuki Ohte, Masayoshi Oikawa, Takahiro Okumura, Masanori Okumura, Katsuya Onishi, Jun-ichi Oyama, Yukio Ozaki, Kan Saito, Tomohiro Sakamoto, Yasushi Sakata, Masashi Sakuma, Masataka Sata, Hisakuni Sekino, Michio Shimabukuro, Wataru Shimizu, Makoto Suzuki, Kunihiro Suzuki, Hiroyuki Takahama, Naohiko Takahashi, Yasuchika Takeishi, Shunsuke Tamaki, Akihiro Tanaka, Syuzo Tanimoto, Hiroki Teragawa, Tomoyuki Tobushi, Takafumi Toita, Kotaro Tokuda, Hiroyuki Tsutsui, Shinichiro Ueda, Hiroki Uehara, Masaaki Uematsu, Hirotaka Watada, Kazuyuki Yahagi, Takahisa Yamada, Hirotsugu Yamada, Tatsuya Yoshida & Akiomi Yoshihisa. (2022) Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial. Hypertension Research 46:2, pages 495-506.
Crossref
Crossref
Chloe Charlwood, Jenika Chudasama, Andrea L. Darling, Hugh Logan Ellis & Martin B. Whyte. (2023) Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. Diabetes Research and Clinical Practice 196, pages 110239.
Crossref
Crossref
Serge A. Jabbour, Nasrien E. Ibrahim & Christos P. Argyropoulos. (2022) Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. Journal of Clinical Medicine 11:20, pages 6051.
Crossref
Crossref
Victor Chien-Chia Wu, Kai-Pin Chiu, Chun-Li Wang, Chiu-Yi Hsu, Hui-Tzu Tu, Yu-Tung Huang, Chih-Hsiang Chang, Chien-Hao Huang, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu & Shang-Hung Chang. (2022) Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Hanny Sawaf, Moarij Qaz, Jeeda Ismail & Ali Mehdi. (2022) The Renal Effects of SGLT2 Inhibitors. EMJ Nephrology, pages 76-83.
Crossref
Crossref
Andrea Cowan, Nivethika Jeyakumar, Yuguang Kang, Stephanie N. Dixon, Amit X. Garg, Kyla Naylor, Matthew A. Weir & Kristin K. Clemens. (2022) Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology 17:6, pages 835-842.
Crossref
Crossref
Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Julia Möllmann, Stephanie Wied, Mathias Hohl, Nikolaus Marx & Michael Lehrke. (2022) Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study. Bone Reports 16, pages 101175.
Crossref
Crossref
Junyi Wang, Zihui Xu, Kang Lv, Yingchun Ye, Deng Luo, Li Wan, Fen Zhou, Ailin Yu, Shuo Wang, Jingcheng Liu & Ling Gao. (2022) The Predictive Value of Serum Calcium on Heart Rate Variability and Cardiac Function in Type 2 Diabetes Patients. Frontiers in Endocrinology 13.
Crossref
Crossref
Dana El Masri, Yasser Jamil & Jocelyne Eid Fares. (2022) Sodium-Glucose Co-Transporter Protein 2 Inhibitors Induced Hypercalcemia: A Case Series and Literature Review. AACE Clinical Case Reports 8:1, pages 30-33.
Crossref
Crossref
Anna Masajtis-Zagajewska, Tomasz Hołub, Katarzyna Pęczek, Agnieszka Makówka & Michał Nowicki. (2021) Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease. Medicina 57:12, pages 1352.
Crossref
Crossref
Priti Meena, Vinant Bhargava, Anil Bhalla, Devinder Rana & Alok Mantri. (2021) Effect of sodium-glucose cotransporter-2 inhibitors on renal handling of electrolytes. Postgraduate Medical Journal 97:1154, pages 819-824.
Crossref
Crossref
Iwona Gorący, Ewa Rębacz-Maron, Jan Korbecki & Jarosław Gorący. (2021) Concentrations of Mg, Ca, Fe, Cu, Zn, P and anthropometric and biochemical parameters in adults with chronic heart failure. PeerJ 9, pages e12207.
Crossref
Crossref
Lucia Del Vecchio, Angelo Beretta, Carlo Jovane, Silvia Peiti & Simonetta Genovesi. (2021) A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs 81:13, pages 1491-1511.
Crossref
Crossref
Elizabeth Van Dril & Christine Schumacher. (2021) Considerations for best practices related to sodium-glucose cotransporter-2 inhibitors and serum potassium levels. American Journal of Health-System Pharmacy 78:15, pages 1367-1368.
Crossref
Crossref
Muhannad Alqudsi, Juan Carlos Q. Velez & Jose Navarrete. (2021) Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Current Opinion in Cardiology 36:4, pages 420-428.
Crossref
Crossref
Antonio De Pascalis, Giuseppe Cianciolo, Irene Capelli, Giuliano Brunori & Gaetano La Manna. (2020) SGLT2 inhibitors, sodium and off-target effects: an overview. Journal of Nephrology 34:3, pages 673-680.
Crossref
Crossref
Joost C. Beusekamp, Jasper Tromp, Eva M. Boorsma, Hiddo J.L. Heerspink, Kevin Damman, Adriaan A. Voors & Peter Meer. (2021) Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. European Journal of Heart Failure 23:6, pages 1049-1052.
Crossref
Crossref
Matthew R Weir, April Slee, Tao Sun, Dainius Balis, Richard Oh, Dick de Zeeuw & Vlado Perkovic. (2021) Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clinical Kidney Journal 14:5, pages 1396-1402.
Crossref
Crossref
Erik J.M. van Bommel, Frank Geurts, Marcel H.A. Muskiet, Adrian Post, Stephan J.L. Bakker, A.H. Jan Danser, Daan J. Touw, Miranda van Berkel, Mark H.H. Kramer, Max Nieuwdorp, Ele Ferrannini, Jaap A. Joles, Ewout J. Hoorn & Daniël H. van Raalte. (2020) SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. Clinical Science 134:23, pages 3107-3118.
Crossref
Crossref
André J. Scheen. (2020) Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 16:10, pages 556-577.
Crossref
Crossref
Jessica A. Dominguez Rieg, Jianxiang Xue & Timo Rieg. (2020) Tubular effects of sodium–glucose cotransporter 2 inhibitors: intended and unintended consequences. Current Opinion in Nephrology & Hypertension 29:5, pages 523-530.
Crossref
Crossref
Cary R. Boyd-Shiwarski, Claire J. Weaver, Rebecca T. Beacham, Daniel J. Shiwarski, Kelly A. Connolly, Lubika J. Nkashama, Stephanie M. Mutchler, Shawn E. Griffiths, Sophia A. Knoell, Romano S. Sebastiani, Evan C. Ray, Allison L. Marciszyn & Arohan R. Subramanya. (2020) Effects of extreme potassium stress on blood pressure and renal tubular sodium transport. American Journal of Physiology-Renal Physiology 318:6, pages F1341-F1356.
Crossref
Crossref
Salva R. Yurista, Herman H. W. Silljé, Harry van Goor, Jan-Luuk Hillebrands, Hiddo J. L. Heerspink, Luiz de Menezes Montenegro, Silke U. Oberdorf-Maass, Rudolf A. de Boer & B. Daan Westenbrink. (2020) Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy 34:3, pages 311-321.
Crossref
Crossref
Oleg Palygin, Denisha Spires, Vladislav Levchenko, Ruslan Bohovyk, Mykhailo Fedoriuk, Christine A. Klemens, Olga Sykes, John D. Bukowy, Allen W. CowleyJr.Jr., Jozef Lazar, Daria V. Ilatovskaya & Alexander Staruschenko. (2019) Progression of diabetic kidney disease in T2DN rats. American Journal of Physiology-Renal Physiology 317:6, pages F1450-F1461.
Crossref
Crossref
Giuseppe Cianciolo, Antonio De Pascalis, Irene Capelli, Lorenzo Gasperoni, Luca Di Lullo, Antonio Bellasi & Gaetano La Manna. (2019) Mineral and Electrolyte Disorders With SGLT2i Therapy. JBMR Plus 3:11.
Crossref
Crossref
Panagiotis I. Georgianos, Maria Divani, Theodoros Eleftheriadis, Peter R. Mertens & Vassilios Liakopoulos. (2019) SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?. Current Medicinal Chemistry 26:29, pages 5564-5578.
Crossref
Crossref
Jiahua Li, Christopher O Fagbote, Min Zhuo, Chelsea E Hawley & Julie M Paik. (2019) Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing. Clinical Kidney Journal 12:5, pages 620-628.
Crossref
Crossref
Zien Zhou, Meg Jardine, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, Richard Oh, Roger Simpson, Nelson B. Watts & Bruce Neal. (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia 62:10, pages 1854-1867.
Crossref
Crossref
Angus Gill, Stephen P. Gray, Karin A. Jandeleit-Dahm & Anna M.D. Watson. (2019) SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. Current Diabetes Reviews 15:5, pages 349-356.
Crossref
Crossref
Joanna Sophia J. Vinke, Hiddo J.L. Heerspink & Martin H. de Borst. (2019) Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Current Opinion in Nephrology and Hypertension 28:4, pages 321-327.
Crossref
Crossref
Amber L. Beitelshees, Bruce R. Leslie & Simeon I. Taylor. (2019) Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. Diabetes 68:6, pages 1109-1120.
Crossref
Crossref
Hillel Sternlicht & George L. Bakris. (2019) Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Current Hypertension Reports 21:2.
Crossref
Crossref
Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu & Kathryn M. Thrailkill. (2019) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes/Metabolism Research and Reviews 35:2, pages e3100.
Crossref
Crossref
Maarten A. de Jong, Sergei I. Petrykiv, Gozewijn D. Laverman, Antonius E. van Herwaarden, Dick de Zeeuw, Stephan J.L. Bakker, Hiddo J.L. Heerspink & Martin H. de Borst. (2019) Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clinical Journal of the American Society of Nephrology 14:1, pages 66-73.
Crossref
Crossref
D. A. Lebedev & A. Yu. Babenko. (2018) Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia. Medical Council:16, pages 100-108.
Crossref
Crossref
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi & David Z.I. Cherney. (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney International 94:1, pages 26-39.
Crossref
Crossref
Mintu P Turakhia, Peter J Blankestijn, Juan-Jesus Carrero, Catherine M Clase, Rajat Deo, Charles A Herzog, Scott E Kasner, Rod S Passman, Roberto Pecoits-Filho, Holger Reinecke, Gautam R Shroff, Wojciech Zareba, Michael Cheung, David C Wheeler, Wolfgang C Winkelmayer, Christoph Wanner, Kerstin Amann, Debasish Banerjee, Nisha Bansal, Giuseppe Boriani, Jared Bunch, Christopher T Chan, David M Charytan, David Conen, Allon N Friedman, Simonetta Genovesi, Rachel M Holden, Andrew A House, Michel Jadoul, Alan G Jardine, David W Johnson, Min Jun, Laura Labriola, Patrick B Mark, Peter A McCullough, Thomas D Nolin, Tatjana S Potpara, Patrick H Pun, Antonio L P Ribeiro, Patrick Rossignol, Jenny I Shen, Manish M Sood, Yusuke Tsukamoto, Angela Yee-Moon Wang, Matthew R Weir, James B Wetmore, Jerzy K Wranicz & Hiro Yamasaki. (2018) Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal 39:24, pages 2314-2325.
Crossref
Crossref
Milton Packer. (2018) Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes, Obesity and Metabolism 20:6, pages 1361-1366.
Crossref
Crossref
María Marques Vidas, Beatriz Dura Gurpide, Esther Rubio, Ana Huerta & José Portolés Pérez. (2018) Dapagliflozin-induced hypercalcemia. Nefrología (English Edition) 38:3, pages 336-337.
Crossref
Crossref
María Marques Vidas, Beatriz Dura Gurpide, Esther Rubio, Ana Huerta & José Portolés Pérez. (2018) Hipercalcemia inducida por dapagliflozina. Nefrología 38:3, pages 336-337.
Crossref
Crossref
Daichi Miyaoka, Akihiro Tsuda, Noriyuki Hayashi, Norikazu Toi, Akiyo Yamasaki, Yuki Nagata, Shinya Nakatani, Masafumi Kurajoh, Shinsuke Yamada, Tomoaki Morioka, Yasuo Imanishi, Masanori Emoto & Masaaki Inaba. (2017) Development of hyperkalemia following treatment with dapagliflozin (DAPA) in a patient with type 2 diabetes after bilateral adrenalectomy. CEN Case Reports 7:1, pages 29-33.
Crossref
Crossref
Jenny E. Blau, Viviana Bauman, Ellen M. Conway, Paolo Piaggi, Mary F. Walter, Elizabeth C. Wright, Shanna Bernstein, Amber B. Courville, Michael T. Collins, Kristina I. Rother & Simeon I. Taylor. (2018) Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3:8.
Crossref
Crossref
Carlos Marin, Frank P. Luyten, Bart Van der Schueren, Greet Kerckhofs & Katleen Vandamme. (2018) The Impact of Type 2 Diabetes on Bone Fracture Healing. Frontiers in Endocrinology 9.
Crossref
Crossref
T.D. Filippatos, V. Tsimihodimos, G. Liamis & M.S. Elisaf. (2018) SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:1, pages 59-63.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
E. C. Christopoulou, T. D. Filippatos, E. Megapanou, M. S. Elisaf & G. Liamis. (2017) Phosphate imbalance in patients with heart failure. Heart Failure Reviews 22:3, pages 349-356.
Crossref
Crossref
Richard E. Gilbert, Christian Mende, Ujjwala Vijapurkar, Sue Sha, Michael J. Davies & Mehul Desai. (2017) Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Therapy 8:2, pages 451-458.
Crossref
Crossref
Edoardo Mannucci & Matteo Monami. (2016) Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. Drug Safety 40:2, pages 115-119.
Crossref
Crossref
Matteo Monami, Ilaria Dicembrini & Edoardo Mannucci. (2016) Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica 54:1, pages 19-36.
Crossref
Crossref
Alexandra L. Migdal, Susan Herzlinger & Martin J. Abrahamson. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
1
24
.
Alexandra L. Migdal, Susan Herzlinger & Martin J. Abrahamson. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
905
927
.
Huilin Tang, Xi Zhang, Jingjing Zhang, Yufeng Li, Liana C. Del Gobbo, Suodi Zhai & Yiqing Song. (2016) Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59:12, pages 2546-2551.
Crossref
Crossref
Hiddo J.L. HeerspinkBruce A. PerkinsDavid H. FitchettMansoor HusainDavid Z. I. Cherney. (2016) Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. Circulation 134:10, pages 752-772.
Crossref
Crossref
Danny Meetoo, Louise Wong & Sabah Alsomali. (2016) Pharmacological options for managing type 2 diabetes. Nurse Prescribing 14:7, pages 330-338.
Crossref
Crossref
Rosemary H Elliott, Vance B Matthews, Caroline Rudnicka & Markus P Schlaich. (2016) Is it time to think about the sodium glucose co‐transporter 2 sympathetically?. Nephrology 21:4, pages 286-294.
Crossref
Crossref
Genjiro Kimura. (2016) Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. Journal of the American Society of Hypertension 10:3, pages 271-278.
Crossref
Crossref
Genjiro Kimura. (2016) Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure. Circulation Journal 80:11, pages 2277-2281.
Crossref
Crossref
Alexandra L. Migdal & Martin J. Abrahamson. 2016. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
1
24
.
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
Arshpreet Kaur & Stephen J Winters. (2015) Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinology, Diabetes & Metabolism Case Reports 2015.
Crossref
Crossref
Karen Whalen, Shannon Miller & Erin St. Onge. (2015) The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Clinical Therapeutics 37:6, pages 1150-1166.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender & David R. Matthews. (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:3, pages 429-442.
Crossref
Crossref
Yuliya LytvynMarko ŠkrtićGary K. YangPaul M. Yip, Bruce A. Perkins & David Z. I. Cherney. (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. American Journal of Physiology-Renal Physiology 308:2, pages F77-F83.
Crossref
Crossref
Virginia Valentine & Deborah Hinnen. (2015) Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes 33:1, pages 5-13.
Crossref
Crossref
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender & David R. Matthews. (2015) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:1, pages 140-149.
Crossref
Crossref
George Maliha & Raymond R. Townsend. (2015) SGLT2 inhibitors: their potential reduction in blood pressure. Journal of the American Society of Hypertension 9:1, pages 48-53.
Crossref
Crossref
Theodoros P. Angelopoulos & John Doupis. (2014) Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective. Advances in Therapy 31:6, pages 579-591.
Crossref
Crossref